The graph illustrates the revenue of a pharma company in three areas, namely Asia, Europe, and America between 2002 and 2006, measured in percentage.
Overall, while the percentage of medicine company’s share sales in Asia witnessed an upward trend, the opposite was true for European and American regions. Additionally, the figures for the Asia area experienced the most significant change in all countries.
In terms of the figures for America and Europe areas which saw decreasing trends, the former had the highest percentage of interest, making up 41 per cent in 2002, whilst the latter began with 34 per cent of total sales. One year later, the proportion of drug company’s share sales in America and Europe was the same at 35 per cent. By 2004, the figure for America continued to decrease by 8 per cent (27 per cent) before increasing back to 29 per cent in the year 2005. Europe, meanwhile, increased slightly to 38 per cent in 2004 for the drug company’s aggregate revenue before declining by 4 per cent one year later. In 2006, these two figures also were the same at 30 per cent.
As for Asia, which saw a falling trend, the proportion of revenues to the pharma manufacturer there was the smallest in 2002 with one-fourth of all areas before increasing by 5 per cent each year, ending the period at 35 per cent in 2004. This figure then rose slightly to 37 per cent in 2005 and culminated with 40 per cent in 2006, becoming the region with by far higher proportion in comparison to others.